TSR-022
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for TSR-022, covering 2021-05-10 to 2026-04-02. Get the full timeline:
Most recent: Clinical Trial Update: TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer [Phase 2]